Claims for Patent: 10,172,921

Summary for Patent: 10,172,921

Title:	Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
Abstract:	The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
Inventor(s):	Couvineau; Alain (Paris, FR), Voisin; Thierry (Paris, FR), Messal; Nassima (Paris, FR), Ogier-Denis; Eric (Paris, FR), Treton; Xavier (Paris, FR)
Assignee:	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)
Application Number:	15/320,827
Patent Claims:	1. A method of treating an inflammatory bowel disease in a subject in need thereof comprising administering to the subject at least one OX1R agonist in an amount sufficient to reduce secretion of a pro-inflammatory cytokine in cells of the subject, wherein the OX1R agonist is a polypeptide selected from the group consisting of SEQ ID NO:2, a polypeptide having at least 70% of identity with SEQ ID NO:3, and a polypeptide having at least 70% of identity with SEQ ID NO:4. 2. The method of claim 1 wherein the inflammatory bowel disease is ulcerative colitis, Crohn's disease, microscopic colitis, infectious colitis caused by bacteria or by virus, radiation colitis, ischemic colitis, pediatric colitis, undetermined colitis, and functional bowel disorders without evident anatomical abnormalities. 3. The method of claim 2, wherein the Crohn's disease specifically affects the colon either with ileitis or without ileitis. 4. The method of claim 1 wherein the OX agonist is selected from the group consisting of small organic molecules, antibodies, aptamers and polypeptides. 5. The method of claim 1 wherein the OX1R agonist is a polypeptide selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4. 6. The method of claim 1 wherein the is fused to a Fc domain to form an immunoadhesin. 7. The method of claim 1 wherein the OX1R agonist is administered to the subject in combination with a standard treatment selected from the group consisting of corticosteroids, immunosuppressive drugs, aminosalicylates, immunosuppressors and biological treatments. 8. The method of claim 7, wherein the aminosalicylate is Mesalazine, Sulfasalazine, Balsalazide, or Olsalazine. 9. The method of claim 7, wherein the immunosuppressor is azathioprine, 6-mercaptopurine, methotrexate, rapamycine, cyclosporine or tacrolimus. 10. The method of claim 7, wherein the biological treatment is Infliximab, Visilizumab, Adalimumab, Vedolizumab, golimumab or tofacitinib. 11. The method of claim 1, wherein the pro-inflammatory cytokine is TNF.alpha..

Details for Patent 10,172,921

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,172,921	2034-06-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	10,172,921	2034-06-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	10,172,921	2034-06-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	10,172,921	2034-06-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	10,172,921	2034-06-24